NantHealth, Inc. (NHIQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NantHealth, Inc. (NHIQ) with AI Score 52/100 (Hold). NantHealth, Inc. operates as a healthcare IT company, providing software and data solutions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026NantHealth, Inc. (NHIQ) Healthcare & Pipeline Overview
NantHealth, Inc. delivers SaaS-based clinical decision support and data solutions to healthcare providers and payers, focusing on oncology and network monitoring. Their Eviti platform and NaviNet solutions aim to improve care coordination and streamline administrative processes within the complex healthcare ecosystem, operating primarily in the US, Canada, and the UK.
Investment Thesis
NantHealth, Inc. operates in the healthcare IT sector, which is experiencing growth due to the increasing need for efficient data management and care coordination. The company's Eviti platform and NaviNet solutions address these needs, particularly in the oncology space. However, with a market capitalization of $0.00B and a negative P/E ratio, the company's financial performance raises concerns. A gross margin of 57.0% indicates some operational efficiency, but a profit margin of -101.2% suggests significant challenges in achieving profitability. Key value drivers include expanding the adoption of Eviti and NaviNet solutions, securing new partnerships with payers and providers, and demonstrating improved financial performance. The high beta of -5.74 suggests high volatility. Investors should carefully consider the company's financial stability and growth prospects before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also higher risk.
- Gross Margin of 57.0% demonstrates the potential for profitability if operating expenses are managed effectively.
- Profit Margin of -101.2% signals significant challenges in achieving profitability and requires close monitoring.
- Beta of -5.74 suggests the stock price moves inversely and more drastically than the market, indicating high volatility.
- Offers SaaS based solutions - clinical decision support and network monitoring - which can lead to recurring revenue streams.
Competitors & Peers
Strengths
- Comprehensive Eviti platform for cancer treatment decision support.
- NaviNet platform for streamlined payer-provider communication.
- SaaS-based business model providing recurring revenue.
- Established presence in the US, Canada, and the UK.
Weaknesses
- Negative profit margin indicating financial challenges.
- High beta suggesting high stock price volatility.
- Limited market capitalization compared to larger competitors.
- Dependence on NantWorks, LLC for resources and support.
Catalysts
- Ongoing: Expansion of the Eviti platform to cover additional cancer types and treatment modalities.
- Ongoing: Strategic partnerships with major health insurance companies to integrate NaviNet.
- Upcoming: Potential geographic expansion into European markets.
- Upcoming: Development and launch of AI-powered analytics for the Quadris data solution.
- Ongoing: Integration of Eviti and NaviNet solutions with telehealth platforms.
Risks
- Ongoing: Intense competition from larger healthcare IT companies.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Potential: Data security and privacy concerns.
- Potential: Technological obsolescence.
- Ongoing: Negative profit margin and financial challenges.
Growth Opportunities
- Expansion of Eviti Platform: NantHealth has the opportunity to expand the capabilities of its Eviti platform to cover a broader range of cancer types and treatment modalities. By incorporating the latest research and clinical guidelines, Eviti can become an even more valuable tool for oncologists, driving increased adoption and revenue growth. The market for oncology clinical decision support systems is projected to reach $1.5 billion by 2028, presenting a significant opportunity for NantHealth to capture a larger share.
- Strategic Partnerships with Payers: Collaborating with major health insurance companies to integrate NaviNet into their existing systems can streamline pre-authorization processes and improve communication with providers. This can lead to increased efficiency and cost savings for payers, making NaviNet an attractive solution. The market for payer-provider communication platforms is estimated at $2.2 billion, offering substantial growth potential for NantHealth through strategic partnerships.
- Geographic Expansion into Europe: Expanding its operations into European markets, where healthcare systems are increasingly focused on digitization and value-based care, represents a significant growth opportunity for NantHealth. By adapting its Eviti and NaviNet solutions to meet the specific needs of European healthcare providers and payers, NantHealth can tap into a new revenue stream. The European healthcare IT market is projected to reach $80 billion by 2027.
- Development of AI-Powered Analytics: Incorporating artificial intelligence (AI) and machine learning (ML) into its Quadris data solution can enable NantHealth to provide more advanced analytics and insights to healthcare providers and payers. This can help them identify trends, predict outcomes, and optimize treatment strategies. The market for AI in healthcare is projected to reach $45 billion by 2026, presenting a significant opportunity for NantHealth to leverage its data assets and expertise.
- Integration with Telehealth Platforms: Integrating its Eviti and NaviNet solutions with telehealth platforms can enable NantHealth to extend its reach and provide its services to a wider range of patients and providers. This can be particularly valuable in rural areas and underserved communities, where access to specialized healthcare services may be limited. The telehealth market is projected to reach $175 billion by 2026, offering a substantial growth opportunity for NantHealth through strategic integrations.
Opportunities
- Expansion of Eviti platform to cover more cancer types.
- Strategic partnerships with major health insurance companies.
- Geographic expansion into European markets.
- Development of AI-powered analytics for Quadris data solution.
Threats
- Intense competition from larger healthcare IT companies.
- Changes in healthcare regulations and reimbursement policies.
- Data security and privacy concerns.
- Potential for technological obsolescence.
Competitive Advantages
- Proprietary Technology: Eviti's comprehensive library of evidence-based treatment standards and protocols provides a competitive advantage.
- Established Relationships: Long-standing relationships with payers and providers create switching costs.
- Data Network Effects: The more users on the NaviNet platform, the more valuable it becomes for all participants.
About NHIQ
NantHealth, Inc., established in 2010 and headquartered in Morrisville, North Carolina, is a healthcare IT company operating in the United States, Canada, and the United Kingdom. As a subsidiary of NantWorks, LLC, NantHealth provides a suite of software and data solutions designed to improve healthcare delivery and administrative efficiency. The company's core offerings include the Eviti platform, a SaaS-based clinical decision support system that centralizes clinical content, treatment cost data from Medicare reimbursements, and treatment toxicity data. Eviti Connect leverages this platform to automate pre-authorization processes, assisting payers and providers in navigating the complexities of cancer care. Additionally, Eviti Advisor allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. NantHealth also offers NaviNet, a suite of SaaS-based solutions that streamline communication and consolidate information between payers and providers. NaviNet Open serves as a payer-provider collaboration platform, while NaviNet AllPayer provides eligibility, benefit, and claim status information to provider offices for commercial and government plans, including Medicare beneficiaries. Furthermore, NantHealth provides OpenNMS, an open-source network monitoring solution for enterprise-grade networks, and Quadris, a data solution that includes multi-data analysis, reporting, and professional services. Originally known as Nant Health, LLC, the company changed its name to NantHealth, Inc. in June 2016.
What They Do
- Offers Eviti, a SaaS-based clinical decision support solution for cancer treatment.
- Provides Eviti Connect, automating pre-authorization for cancer care.
- Offers Eviti Advisor, giving physicians access to evidence-based treatment standards.
- Delivers NaviNet, a suite of SaaS solutions for payer-provider communication.
- Provides NaviNet Open, a platform for collaboration between health plans and providers.
- Offers NaviNet AllPayer, providing eligibility and claim status information.
- Provides OpenNMS, an open-source network monitoring solution.
- Offers Quadris, a data solution for multi-data analysis and reporting.
Business Model
- Software-as-a-Service (SaaS): Generates recurring revenue through subscriptions to its Eviti and NaviNet platforms.
- Data Solutions: Provides data analysis, reporting, and professional services through its Quadris solution.
- Platform Integration: Earns revenue by integrating its solutions with payer and provider systems.
Industry Context
NantHealth, Inc. operates within the healthcare IT sector, a market driven by the increasing adoption of electronic health records (EHRs), the growing need for interoperability, and the rising demand for data analytics solutions. The industry is characterized by intense competition, with established players like ACHKF (Allscripts Healthcare Solutions) and ALDNF (Cerner Corporation) vying for market share. NantHealth's focus on oncology and payer-provider communication positions it within specific niches of this broader market. The healthcare IT market is projected to continue growing, fueled by government initiatives promoting healthcare digitization and the increasing prevalence of chronic diseases.
Key Customers
- Healthcare Providers: Oncologists, hospitals, and clinics use Eviti to support treatment decisions.
- Health Insurance Companies: Payers use NaviNet to streamline communication and pre-authorization processes.
- Enterprise-Grade Networks: Organizations use OpenNMS for network monitoring.
Financials
Chart & Info
NantHealth, Inc. (NHIQ) stock price: Price data unavailable
Latest News
No recent news available for NHIQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NHIQ.
Price Targets
Wall Street price target analysis for NHIQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates NHIQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Rao Haris Naseem FACC,
CEO
Rao Haris Naseem is the CEO of NantHealth, Inc. His background includes extensive experience in the healthcare sector, with a focus on clinical and technological innovation. He is a Fellow of the American College of Cardiology (FACC), indicating expertise in cardiovascular medicine. His leadership aims to drive the company's growth through strategic partnerships and technological advancements in healthcare IT. He is responsible for overseeing the company's operations and strategic direction.
Track Record: Since becoming CEO, Rao Haris Naseem has focused on expanding NantHealth's product offerings and strengthening its relationships with key stakeholders in the healthcare industry. Key achievements include enhancing the Eviti platform's capabilities and securing new partnerships with payers and providers. He has also overseen the development of AI-powered analytics for the Quadris data solution. His leadership is geared towards improving the company's financial performance and market position.
NHIQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NantHealth, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available and may be subject to less regulatory oversight compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity and information.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Lower trading volumes can make it difficult to buy or sell shares without significantly impacting the price.
- Information Scarcity: Lack of readily available financial information and regulatory oversight increases the risk of fraud or mismanagement.
- Price Volatility: OTC stocks are often subject to greater price swings due to lower trading volumes and speculative trading.
- Delisting Risk: The company may not meet the requirements for continued listing on the OTC market, leading to potential delisting.
- Penny Stock Rules: OTC stocks may be subject to penny stock rules, which impose additional restrictions and disclosure requirements on brokers.
- Verify the company's registration and regulatory filings with the SEC or other relevant authorities.
- Review the company's financial statements, if available, and assess its financial health and performance.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Consult with a qualified financial advisor before investing.
- Check for any legal or regulatory actions against the company or its management.
- Established Operations: NantHealth, Inc. has been in operation since 2010, indicating some level of stability.
- Subsidiary of NantWorks, LLC: Being a subsidiary of NantWorks, LLC provides some level of credibility.
- SaaS-Based Solutions: Offering SaaS-based solutions suggests a recurring revenue model.
- CEO with Relevant Experience: Rao Haris Naseem's background in healthcare and cardiology lends some credibility to the company's leadership.
Common Questions About NHIQ
What does NantHealth, Inc. do?
NantHealth, Inc. operates as a healthcare IT company, providing software and data solutions designed to improve healthcare delivery and administrative efficiency. Its core offerings include the Eviti platform, a SaaS-based clinical decision support system for cancer treatment, and the NaviNet platform, which streamlines communication and information exchange between payers and providers. The company also offers network monitoring solutions and data analytics services, targeting healthcare providers, health insurance companies, and enterprise-grade networks. NantHealth aims to enhance care coordination, reduce costs, and improve patient outcomes through its technology solutions.
What do analysts say about NHIQ stock?
AI analysis is currently pending for NHIQ. However, considering the company's financials, including a $0.00B market cap, negative P/E ratio, and a profit margin of -101.2%, analysts would likely focus on the company's ability to improve its financial performance and achieve profitability. Key valuation metrics to watch include revenue growth, gross margin, and operating expenses. Growth considerations would likely center on the company's ability to expand its Eviti and NaviNet platforms, secure new partnerships, and penetrate new markets. The high beta of -5.74 also suggests high volatility, which analysts would consider.
What are the main risks for NHIQ?
NantHealth, Inc. faces several risks, including intense competition from larger healthcare IT companies, potential changes in healthcare regulations and reimbursement policies, and data security and privacy concerns. The company's negative profit margin and financial challenges also pose a significant risk. Additionally, the company faces the risk of technological obsolescence, as the healthcare IT industry is rapidly evolving. As an OTC stock, NHIQ faces additional risks related to liquidity, information scarcity, and price volatility. These risks could negatively impact the company's financial performance and market value.
What are the key factors to evaluate for NHIQ?
NantHealth, Inc. (NHIQ) currently holds an AI score of 52/100, indicating moderate score. Key strength: Comprehensive Eviti platform for cancer treatment decision support.. Primary risk to monitor: Ongoing: Intense competition from larger healthcare IT companies.. This is not financial advice.
How frequently does NHIQ data refresh on this page?
NHIQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NHIQ's recent stock price performance?
Recent price movement in NantHealth, Inc. (NHIQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive Eviti platform for cancer treatment decision support.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NHIQ overvalued or undervalued right now?
Determining whether NantHealth, Inc. (NHIQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NHIQ?
Before investing in NantHealth, Inc. (NHIQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and will provide further insights.